12874 results
-
List item
Human medicine European public assessment report (EPAR): Pemetrexed Pfizer (previously known as Pemetrexed Hospira UK Limited)
pemetrexed ditromethamine, Carcinoma, Non-Small-Cell Lung; Mesothelioma
Date of authorisation: 24/04/2017,
, Revision: 7, Withdrawn, Last updated: 29/07/2021
as Pemetrexed Hospira UK Limited) Carcinoma, Non-Small-Cell … as Pemetrexed Hospira UK Limited) … public Pemetrexed Hospira UK Limited pemetrexed This is a summary … -
List item
Human medicine European public assessment report (EPAR): Taxespira (previously Docetaxel Hospira UK Limited )
docetaxel trihydrate, Stomach Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung
Date of authorisation: 28/08/2015,, Revision: 8, Withdrawn, Last updated: 15/10/2019
previously Docetaxel Hospira UK Limited ) Stomach Neoplasms Prostatic … previously Docetaxel Hospira UK Limited … different indication, such as a limited indication that will allow … -
List item
Orphan designation: Cultured allogeneic corneal limbal stem cells for: Treatment of limbal stem cell deficiency
Date of designation: 15/10/2014, Positive, Last updated: 12/11/2014designation for the treatment of limbal stem cell deficiency … Cultured allogeneic corneal limbal stem cells for the treatment … cells for the treatment of limbal stem cell deficiency … -
List item
Herbal medicinal product: Tiliae tomentosae flos
Tilia tomentosa Moench, Silver lime flower, F: Assessment finalised, Last updated: 09/07/2012Tiliae tomentosae flosSilver lime flowerTilia tomentosa Moench … tomentosa Moench, flos (silver lime) EMA/HMPC/160869/2010 22/03/2010 … tomentosa Moench Silver lime flower … -
List item
Orphan designation: Autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin for: Treatment of mantle cell lymphoma
Date of designation: 23/02/2011, Positive, Last updated: 04/03/2011idiotype coupled to keyhole limpet hemocyanin … idiotype coupled to keyhole limpet hemocyanin for the treatment … idiotype coupled to keyhole limpet hemocyanin for the treatment … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-001274-PIP01-12, Route(s) of administration: Subcutaneous use, Pharmaceutical form(s): Solution for injection
Decision date: 20/08/2012, Last updated: 17/09/2012, Compliance check: Xidiotype coupled to keyhole limpet hemocyanin Therapeutic area … idiotype coupled to keyhole limpet haemocyanin (EMEA-001274-PIP01-12) 7 … idiotype coupled to keyhole limpet haemocyanin (EMEA-001274-PIP01-12 … -
List item
Herbal medicinal product: Tiliae flos
Tilia cordata Miller, Tilia platyphyllos Scop., Tilia x vulgaris Heyne, Lime flower, F: Assessment finalised, Last updated: 15/02/2023Tilia x vulgaris Heyne, flos (lime flower) - First version EMA/HMPC/160868/2010 … Scop., Tilia x vulgaris Heyne Lime flower … -
List item
Orphan designation: Autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin for: Treatment of follicular lymphoma
Date of designation: 28/08/2006, Positive, Last updated: 14/06/2012idiotype coupled to keyhole limpet hemocyanin … idiotype coupled to keyhole limpet haemocyanin for the treatment … idiotype coupled to keyhole limpet haemocyanin for the treatment … -
List item
Orphan designation: L-cysteine, L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-complex with keyhole limpet haemocyanin for: Treatment of glioma
Date of designation: 27/10/2011, Withdrawn, Last updated: 04/12/2020L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-complex with keyhole limpet haemocyanin … L-leucyl-L-alpha-glutamyl-L-alpha-glutamyl-L-lysyl-L-lysylglycyl- L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-alpha-aspartyl-L-histidyl- S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-complex with keyhole limpet haemocyanin for the treatment … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): L-Cysteine, L-leucyl-L-α-glutamyl-L-α-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-α -aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-, complex with keyhole limpet haemocyanin
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: EMEA-001810-PIP01-15, Route(s) of administration: Intradermal use, Pharmaceutical form(s): Powder for solution for injection
Decision date: 30/10/2015, Last updated: 22/12/2015, Compliance check: Xaspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-, complex with keyhole limpet haemocyanin OncologyP/0259/2015EMEA-001810-PIP01-15 … aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-, complex with keyhole limpet haemocyanin (EMEA-001810-PIP01-15 … -
List item
News: European Medicines Agency revises MUMS / limited-market policy
CVMP, Last updated: 18/06/2013Medicines Agency revises MUMS / limited-market policy … Medicines Agency revises MUMS / limited-market policy … Medicines Agency amends MUMS limited market policy 13 June … -
List item
Classifications as minor-use-minor-species and limited-market according to former EMA policy
Last updated: 06/12/2021minor-use-minor-species and limited-market according to former EMA polic … minor-use-minor-species and limited-market according to former EMA polic …
-
List item
Veterinary limited markets
Last updated: 21/04/2023Veterinary limited markets … Veterinary limited markets … product as intended for a limited market according to Article …
-
List item
Maximum residue limits (MRL)
Last updated: 14/02/2023Maximum residue limits (MRL … found under 'Maximum residue limits'. maximum residue limit (MRL) is the maximum allowed … establishment of residue limits of pharmacologically active …
-
List item
National expert: Jobst Limberg, Federal Institute for Drugs and Medical Devices (updated)
- Declaration of interests - 39.29 KB | PDF
- Curriculum Vitae - 30.65 KB | PDF
Jobst Limberg … Jobst Limberg … Vitae Personal information Jobst Limberg Work experience … -
List item
Maximum residue limit opinions
Last updated: 01/07/2022Maximum residue limit opinions … Maximum residue limit opinions … establishment of maximum residue limits Procedure no: EMEA/V/MRL/004828/EXTN/0002 …
-
List item
Classification of a product as intended for a limited market and eligibility for authorisation under Article 23 of Regulation (EU) 2019/6 (Applications for limited markets)
Last updated: 23/07/2021product as intended for a limited market and eligibility for … 2019/6 (Applications for limited markets … product as intended for a limited market and eligibility for …
-
List item
Veterinary limited markets
Last updated: 04/02/2016Veterinary limited markets … Veterinary limited markets …
-
List item
Veterinary limited markets
Last updated: 27/04/2010Veterinary limited markets … Veterinary limited markets …
-
List item
National expert: Ulla Wändel Liminga, Medical Products Agency (updated)
- Declaration of interests - 39.44 KB | PDF
- Curriculum Vitae - 29.78 KB | PDF
Ulla Wändel Liminga … Ulla Wändel Liminga … information Ulla Wändel Liminga Work experience … -
List item
Maximum residue limits
Last updated: 31/12/2009Maximum residue limits … review of Maximum Residue Limits (MRLs) PDF icon application/pdf … Governance Maximum residue limit …
-
List item
Maximum residue limit assessment reports
Last updated: 12/03/2010Maximum residue limit assessment reports … Maximum residue limit assessment reports …
-
List item
Maximum Residue Limits Q&A: Introduction
Last updated: 31/12/2009Maximum Residue Limits Q&A: Introduction … Union ”: Maximum residue limits guidelines (MRL …
-
List item
Pending EC decisions on maximum residue limits
Last updated: 12/03/2010decisions on maximum residue limits … decisions on maximum residue limits …
-
List item
Direct healthcare professional communication (DHPC): Visudyne (verteporfin): Information on the continuing supply limitation until end of 2023
Active substance: verteporfin, DHPC type: Medicine shortage, Last updated: 12/08/2022on the continuing supply limitation until end of 2023 Myopia … on the continuing supply limitation until end of 2023 12/08/2022 … on the continuing supply limitation until end of 2023 Dear …